Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

Next Previous
Trial Profile

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Relacorilant (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms ROSELLA
  • Sponsors Corcept Therapeutics

Most Recent Events

  • 29 May 2026 Results published in the Media Release
  • 29 May 2026 According to a Corcept Therapeutics media release, data from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 21 Apr 2026 According to a Corcept Therapeutics media release, data from this trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented in an oral presentation on Friday, May 29, 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top